Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aerosol Drug Inhibition of Lung Cancer

a technology of lung cancer and aerosol, which is applied in the field of aerosol drug inhibition of lung cancer, can solve the problems of cancer-related deaths, limited use of traditional systemic routes of drug delivery, and limited drug delivery

Inactive Publication Date: 2008-01-10
KNIGHT J VERNON +2
View PDF3 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lung cancer remains the leading cause of cancer-related deaths.
Traditional systemic routes of drug delivery have yielded limited results because of the inability to provide effective concentrations at the sites of cancer without encountering dose-limiting toxicity.
Its use, however, may be limited by acquired resistance of tumor cells to the drug.
The drug is administered intravenously in a clinical setting since its bioavailability is poor after oral administration.
However, one limiting factor is that cyclosporin A is a powerful immunosuppressive agent and can cause nephrotoxicity (30).
The prior art is deficient in the lack of a method of inhibiting the growth of pulmonary tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aerosol Drug Inhibition of Lung Cancer
  • Aerosol Drug Inhibition of Lung Cancer
  • Aerosol Drug Inhibition of Lung Cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Chemicals

[0042] Paclitaxel was obtained from SuperGen (San Ramon, Calif.). Cyclosporin A was purchased from Chemwerth (Woodridge, Conn.). Dilauroylphosphatidylcholine (DLPC) was purchased from Avanti Polar Lipids (Alabaster, Ala.). Organic solvents (HPLC grade) were obtained from Fisher Scientific. Sterile water for irrigation was purchased from Baxter Healthcare Corporation (Deerfield, Ill.).

example 2

Animals

[0043] Female BALB / c mice (7-8 weeks old) were obtained from Harlan-Sprague Dawley (Indianapolis, Ind.) and housed in standard cages with food and water provided ad libitum. Experiments were performed with the approval of the Institutional Animal Care and Use Committee.

example 3

Cell Culture and Animal Model

[0044] The mouse renal carcinoma cell line (Renca) was provided by and maintained by serial passages as described by Dr. Robert Wiltrout, National Cancer Institute (Frederick, Md.). Prior to in vivo implantation, Renca cells were cultured in vitro for 2 passages as described previously (14). To induce pulmonary metastases, 100,000 cells were injected intravenously in 0.2 ml saline via tail vein in syngeneic BALB / c mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
transition temperatureaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention provides a method of inhibiting growth of lung metastases in an individual comprising the steps of administering a dose of a lipid-drug enhancer liposomal complex and, in sequence, administering a dose of a lipid-anticancer drug liposomal complex. Furthermore, the lipid-drug enhancer liposomal complex may be administered in a continuing dose with the lipid-anticancer drug liposomal complex whereby both liposomal complexes are mixed in the nebulizer. Methods of inhibiting growth of lung metastases in an individual by the sequential administration via aerosolization of a dilauroylphosphatidylcholine-cyclosporin A liposomal complex and a dilauroylphosphatidylcholine-paclitaxel liposomal complex are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This non-provisional application claims benefit of provisional U.S. Ser. No. 60 / 381,767, filed May 20, 2002, now abandoned.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] This invention relates to the fields of pharmacology and cancer treatment. More specifically, this invention relates to the combination of anticancer drugs with a drug-enhancing agent administered by aerosol for the treatment of lung cancer in vivo. [0004] 2. Description of the Related Art [0005] Lung cancer remains the leading cause of cancer-related deaths. Traditional systemic routes of drug delivery have yielded limited results because of the inability to provide effective concentrations at the sites of cancer without encountering dose-limiting toxicity. An aerosol route for immediate administration of various therapeutic agents to the lungs has been described (1-3). Inhalation of liposomal formulations of the lipophilic anticancer drug, 9-nitroc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/12A61P11/00A61K9/00A61K9/127A61K31/337A61K31/4745A61K31/704A61K31/7048A61K38/13
CPCA61K9/0078A61K9/127A61K31/337A61K31/4745A61K31/704A61K31/7048A61K38/13A61K2300/00A61P11/00
Inventor KNIGHT, J. VERNONWALDREP, J. CLIFFORDKOSHKINA, NADEZHDA
Owner KNIGHT J VERNON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com